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 To determine the epidemiology of human herpesvirus 
type 8 (HHV-8) among non-Amazonian native populations, 
we conducted a cross-sectional study in Brazil, Bolivia, and 
Paraquay. Our data show striking ethnic and geographic 
variations in the distribution of HHV-8 seroprevalences in 
Amazonian (77%) and non-Amazonian native populations 
(range 0%–83%). 
Human herpesvirus type 8 (HHV-8) is the etiologic agent of all forms of Kaposi sarcoma, primary effu-
sion lymphoma, and certain lymphoproliferative diseases. 
HHV-8 seroprevalence is low (<5%) in northern Europe 
and North America, where HIV-seropositive homosexual 
men represent the highest risk group. HHV-8 infection is 
endemic in eastern and central Africa, with seroprevalenc-
es >50% in some adult populations (1). However, the high-
est HHV-8 seroprevalences worldwide (>80% in adults) 
have been reported in Native Americans from the Amazon 
region of Brazil (2–5), French Guiana (6), and Ecuador 
(7). In HHV-8–endemic areas in Africa and the Amazon, 
the sharp and linear increases of HHV-8 seroprevalence in 
children before puberty, with only modest increases later 
in life (3,5), and the association of HHV-8 seropositiv-
ity in children with having at least 1 fi rst-degree relative 
who is seropositive (8) suggest nonsexual transmission of 
HHV-8 within families, probably through saliva (9). In-
deed, this hypothesis is supported by the fi nding that, in 
Native Americans, nearly one fourth of HHV-8–seroposi-
tive persons, and <40% of children, shed HHV-8 DNA in 
their saliva (5). A particular feature of the epidemiology 
of HHV-8 in Native Americans is that infection is caused 
by a recently discovered distinct and unique HHV-8 strain 
(subtype E) (2,5,7). Previous research has also shown 
that HHV-8 seroprevalence is 10-fold lower in nonnative 
populations living in similar conditions in adjacent remote 
geographic areas, which suggests that HHV-8 infection in 
Native Americans may be associated with specifi c risk fac-
tors or behaviors but not with environmental factors (5). 
Little is known, however, of the epidemiology of HHV-8 
among other Native American populations. We conducted 
a cross-sectional study to investigate whether HHV-8 was 
also endemic among Native American populations living 
outside Amazonia.
The Study
Serum samples from the Wai Wai, a Native American 
tribe living in the Mapuera village in the area of the Trom-
betas, a tributary of the Amazon River, in Pará State, Bra-
zil, were collected during May–June 2007. In addition, we 
obtained archived serum samples (collected during studies 
conducted during1972–1988 and frozen at –20°C) from 
5 non-Amazonian Native American populations (10–13). 
The following non-Amazonian ethnic groups were evalu-
ated: 1) the Xikrin, Gorotire, and Kuben-Kran-Kegn, who 
live in a transition region between the Amazonian forest 
and the savannah of central Brazil; 2) the Krahó, from a 
savannah region of central Brazil; 3) the Ayoreo, from 3 
different localities of the Chaco region of Bolivia and Para-
guay; 4) the Kaingang, from Ivaí and Rio das Cobras in 
southern Brazil; and 5) the Guarani, from Rio das Cobras, 
in southern Brazil (Figure). The genetic and serologic stud-
ies were approved by the Brazilian National Ethics Com-
mission (CONEP Resolutions. 123/98 and 005/2003). 
Research aims and methods of the previous studies 
were diverse, but all enrolled participants (range 1–70 years 
of age) were enlisted without any previous selection from 
those who agreed to voluntarily participate in the study 
and convened at a specifi c place in the village to provide 
serum samples. Informed consent procedures were done 
individually, mostly verbally, with the assistance of local 
indigenous health agents. Consent for children <15 years 
of age was given by a parent or guardian (10–13). Antibod-
ies to HHV-8 latency-associated nuclear (LANA) and lytic 
antigens were determined by immunofl uorescence assays 
(IFA) at a 1:40 starting dilution, using the body cavity–
based lymphoma (BCBL) 1 cell line. Punctuate nuclear 
staining in noninduced BCBL-1 cells was considered posi-
tive for LANA antibodies. The viral lytic cycle was in-
duced by incubating BCBL-1 cells with 20 ng/mL of 12-O-
tetradecanoylphorbol-13–acetate (TPA) (Sigma, St. Louis, 
MO, USA) for 96 hours. Entire cell fl uorescence in ≈20% 
of TPA-treated cells was considered positive for antibodies 
to the lytic-phase antigens (5). Overall HHV-8 seroposi-
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tivity was defi ned as positivity by any of these IFAs, but 
results are also presented by assay type. Chi-square statis-
tics were used to estimate the associations between HHV-8 
seropositivity and sex and age groups.
The prevalence of HHV-8 antibodies by any assay 
ranged from 0% to 83% in the various groups (Table 1). 
HHV-8 seroprevalence did not differ between men and boys 
(222/350, 63%) and women and girls (265/410, 64%) (p = 
0.7). We found an overall signifi cant trend for increasing 
prevalence with age (84/150, 56%) in children 0–12 years 
of age, 63% (282/450) in young adults 13–40 years of age, 
and 76% (121/160) in adults >40 years (p trend<0.001), 
although these results mostly refl ected age seroprevalence 
patterns in the largest group (Wai Wai). The highest sero-
prevalences were observed in the populations living in the 
Amazon (77%) and in the transitional geographic area be-
tween the Amazon forest and the savannah of central Brazil 
(50%–83%). The Ayoreo from Bolivia and Paraguay had 
an intermediate seroprevalence (18%–45%), and the lowest 
seroprevalence was observed among Native Americans liv-
ing in southern Brazil (Guarani and Caingang, 0%–14%), 
following a north-south gradient.
Conclusions
Our data show striking geographic and ethnic varia-
tions in the distribution of HHV-8 seroprevalences among 
South American native populations. Previous reports have 
shown that most Amazonian Native American groups have 
high HHV-8 seroprevalence, but substantial between-
group and sometimes within-group differences have been 
observed in previous studies (Table 2). These differences 
could be explained, to some extent, by the different tech-
niques that have been used to detect HHV-8 antibodies. No 
clearly defi ned acceptable standard test exists to determine 
HHV-8 seropositivity, and different assays have shown dif-
ferent levels of accuracy, including intra-assay variations 
when the same test is performed in different laboratories 
(14). Therefore, comparing HHV-8 seroprevalence in dif-
ferent settings has limitations. In this study, the same as-
says (anti-LANA and anti-lytic IFAs) were performed on 
all samples from all populations in 1 laboratory, and ma-
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Figure. Locations and respective human herpesvirus type 8 
seroprevalence rates (%) of Native American populations studied, 
South America.
Table 1. Prevalence of HHV-8 antibodies in Amazonian and non-Amazonian Native American populations, by assay type* 
Population, locality† 
No. persons 
tested
No. (%) persons HHV-8 seropositive
By IFA-LANA or 
IFA-lytic By IFA-LANA By IFA-lytic
By IFA-LANA and 
IFA-lytic
Wai-Wai, Mapuera, Brazil 530 397 (75) 372 (70) 204 (38) 177 (33) 
Xikrin, Caeteté, Brazil 30 15 (50) 13 (43) 6 (20) 4 (13) 
Gorotire, PI Gorotire, Brazil 30 20 (67) 20 (67) 7 (23) 7 (23) 
Kuben-Kran-Kegn, Nilo Peçanha, Brazil 30 25 (83) 25 (83) 4 (13) 4 (13) 
Krahó, Cachoeira, Brazil 20 12 (60) 10 (50) 10 (50) 7 (35)  
Ayoreo,Tobité, Bolivia 18 5 (28) 5 (28) 2 (11) 2 (11) 
Ayoreo, Pozo Verde, Bolivia 17 3 (18) 2 (12) 1 (6) 0 (0) 
Ayoreo, M Auxiliadora, Paraguay 20 9 (45) 9 (45) 7 (35) 7 (35) 
Kaingang, Ivaí, Brazil 30 0 0 0 0
Kaingang, Rio das Cobras, Brazil 26 0 0 0 0
Guarani, Rio das Cobras, Brazil 29 4 (14) 4 (14) 2 (7) 2 (7) 
*HHV-8, human herpesvirus type 8; IFA, immunofluorescence assay; LANA, latency-associated nuclear antigen. 
†Listed in a north–south gradient (Figure). 
HHV 8 Seroprevalence in Native Americans
jor variations in the distribution of HHV-8 seroprevalence 
were observed. The low HHV-8 seroprevalence among the 
Guarani (14%) and its absence among 56 Kaingang per-
sons, both populations living in southern Brazil, contrasts 
with the high seroprevalences in populations living in cen-
tral Brazil and Amazonia.
Although this study lacks the power to assess statis-
tically signifi cant differences in HHV-8 seroprevalences 
by geographic region, the variation in the distribution of 
HHV-8 is intriguing. Current consensus suggests that the 
Bering Strait land bridge was prehistorically the only entry 
point to the American landmass and that human migration 
occurred not earlier than 15,000 years ago, using the Pa-
cifi c Coast route, with subsequent spread to the Amazon 
and the rest of South America. The presence of the Guarani 
and Kaingang at their present locations is thought to have 
occurred comparatively recently, ≈1,000–2,000 years ago 
(15). This history suggests that the differences in HHV-8 
seroprevalence between these groups and others from the 
Amazon may be caused by more recent events. 
Phylogenetic analysis of HHV-8 strains obtained 
from Native Americans living in different regions and 
from different groups could contribute to establishing the 
period when HHV-8 was introduced in Amazonian and 
non-Amazonian native populations. However, the use of 
archived serum samples in the present series precluded the 
exploration of genetic characteristics of HHV-8 strains in 
the non-Amazonian groups. Another limitation concerns 
the recruitment of study participants; thus, selection bias 
cannot be excluded. As previously reported (5,7), and, in 
contrast to other populations, all Native American groups 
exhibited a higher prevalence of antibodies against LANA 
than against lytic antigen, although the signifi cance of this 
fi nding cannot be determined in this study. Larger prospec-
tive population-based studies and detailed historical, epide-
miologic, and genetic investigations are needed to explore 
the substantial epidemiologic differences in HHV-8 infec-
tion found between Amazonian and non-Amazonian Na-
tive American populations.
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Table 2. Previous human herpesvirus type 8 seroprevalence studies in Amazonian Native American populations* 
Population† No. positive/no. tested (%) HHV-8 assay used‡ Reference
Wai Wai, Brazil 275/339 (81) IFA-LANA, IFA-Lytic (5)
Zoé, Brazil 18/49 (37) EIA-ORF59/0RF65/K8.1 (4)
Emerillon, French Guiana 12/78 (15) IFA-Lytic (ABI test) (6)
Palikur, French Guiana 22/167 (13) IFA-Lytic (ABI test) (6)
Wayana, French Guiana 41/144 (28) IFA-Lytic (ABI test) (6)
wayampi, French Guiana 93/302 (31) IFA-Lytic (ABI test) (6)
Wayampi, Brazil 85/123 (69) IFA-LANA, IFA-Lytic (3)
Wayampi, Brazil 28/33 (85) IFA-LANA, EIA w-virus (2)
Tiriyó, Brazil 381/664 (57) IFA-LANA, IFA-Lytic (3)
Tiriyó, Brazil 30/35 (86) IFA-LANA, EIA w-virus (2)
Tiriyó, Brazil 24/56 (43) EIA-ORF59/0RF65/K8.1 (4)
Huaroni, Ecuador 38/38 (100) IFA-LANA, EIA-K8.1, EIA-ORF73 (7)
Siona, Ecuador 10/41 (24) IFA-LANA, EIA-K8.1, EIA-ORF73 (7)
Apalaí, Brazil 8/44 (18) IFA-LANA, EIA w-virus (2)
Arara-Laranja, Brazil 18/92 (20) EIA-ORF59/0RF65/K8.1 (4)
Arara-Laranjal, Brazil 0/11 (0) IFA-LANA, EIA w-virus (2)
Kararao, Brazil 6/24 (25) EIA-ORF59/0RF65/K8.1 (4)
Asurini-Koatinemo, Brazil 7/10 (70) IFA-LANA, EIA w-virus (2)
Munduruku, Brazil 36/40 (90) IFA-LANA, EIA w-virus (2)
Araweté, Brazil 12/17 (71) IFA-LANA, EIA w-virus (2)
Parakanã, Brazil 27/30 (90) IFA-LANA, EIA w-virus (2)
Xikrin, Brazil 20/34 (59) IFA-LANA, EIA w-virus (2)
Karitiana, Brazil 12/25 (48) IFA-LANA, EIA w-virus (2)
Suruí, Brazil 15/17 (88) IFA-LANA, EIA w-virus (2)
Mekranoti, Brazil 34/52 (65) IFA-LANA, EIA w-virus (2)
Cinta Larga, Brazil 1/14 (7) IFA-LANA, EIA w-virus (2)
*ABI, Advanced Biotechnologies Inc (Columbia, MD, USA); EIA, enzyme immunoassay; IFA, immunofluorescence assay; LANA, latency-associated 
nuclear antigen; ORF, open reading frame; w-virus, whole-virus assay. 
†Listed in north-south gradient (Figure). 
‡Only series with >10 persons are presented. 
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